The owners of the company “OZONE Pharmaceuticals” put the company up for sale. About it writes “Kommersant” citing its sources. According to the publication, the decision to sell the asset due to low profitability of cheap drugs that form the basis of a portfolio company.
The publication provides the presentation for sale of a pharmaceutical company, whose characteristics (location of production sites, size and composition of the portfolio, the volume of production) coincide with the data “OZONE Pharmaceuticals.” The sources also confirmed that we are talking about this company. The owners of the “OZONE Pharmaceuticals” did not comment on this information.
The company “OZONE Pharmaceuticals” was founded in 2001 in the city of Zhigulevsk, Samara region, in 2003 there was launched the first production site of the company in 2017, she opened a second plant in Togliatti. The pharmaceutical portfolio includes more than 300 items of finished pharmaceutical products are generics, most of which belong to the lower price segment.
According to DSM Group, in 2019, the sale of “OZONE Pharmaceuticals” decreased by 31% to RUB 17.1 bn year-on-year. Development Director at RNC Pharma Nikolai Bespalov estimated the cost of “OZONE Pharmaceuticals” 7-10 billion rubles.
Russian pharmaceutical companies have repeatedly pointed to the unprofitability of production of cheap drugs in Russia. This, in turn, is about drugs included in the VED list, the prices of which are regulated by the government. In April 2020 seven Russian companies, including “OZONE Pharmaceuticals”, said the Ministry of industry and trade about the possible discontinuation of more than 50 INNS medications, as their implementation is necessary to carry out at prices below cost, reminds “Kommersant”.